On July 10, 2025, the shares in LN Future Invest AB (previously Ellen Aktiebolag) (the "Company") were given observation status with reference to information that the Company had entered into a conditional agreement for the sale of the Company's operations to Addeira Pharmaceuticals AB.
On August 19, 2025, the Company issued a press release with information that it had completed the sale of its operational business.
Today, August 29, 2025, the Company issued a press release with its half-year report for 2025. The press release also included information about changes to the Company's board of directors, resulting in the board of directors not meeting applicable quorum requirements.
The rules of Nasdaq First North Growth Market state that an issuer can be given observation status if any circumstance exists that results in substantial uncertainty regarding the issuer or the pricing of its financial instruments.
With reference to the above, Nasdaq Stockholm AB decides to update the grounds for the observation status for the shares in LN Future Invest AB (LNFI, ISIN code SE0014730347, order book ID 42472).
For further information about this exchange notice please contact Enforcement & Investigations, telephone +46 8 405 70 50.
